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Abstract: Stem cell therapy is one of the most promising candidate treatments for spinal cord injury.
Research has shown optimistic results for this therapy, but clinical limitations remain, including
poor viability, engraftment, and differentiation. Here, we isolated novel peripheral nerve-derived
stem cells (PNSCs) from adult peripheral nerves with similar characteristics to neural-crest stem
cells. These PNSCs expressed neural-crest specific markers and showed multilineage differentiation
potential into Schwann cells, neuroglia, neurons, and mesodermal cells. In addition, PNSCs showed
therapeutic potential by releasing the neurotrophic factors, including glial cell-line-derived neu-
rotrophic factor, insulin-like growth factor, nerve growth factor, and neurotrophin-3. PNSC abilities
were also enhanced by their development into spheroids which secreted neurotrophic factors several
times more than non-spheroid PNSCs and expressed several types of extra cellular matrix. These
features suggest that the potential for these PNSC spheroids can overcome their limitations. In
an animal spinal cord injury (SCI) model, these PNSC spheroids induced functional recovery and
neuronal regeneration. These PNSC spheroids also reduced the neuropathic pain which accompanies
SCI after remyelination. These PNSC spheroids may represent a new therapeutic approach for
patients suffering from SCI.
Keywords: peripheral nerve-derived stem cells; spheroids; spinal cord injury; neuroregeneration;
functional recovery; neurotrophic factor
1. Introduction
Spinal cord injury (SCI) is mainly caused by external injuries, but also by vascular dis-
orders, tumors, and infections. SCI can cause medical complications that include temporary
or permanent impairments of motor, sensory, and autonomic functions. Currently, only a
few treatments exist for SCI: the administration of high doses of corticosteroids within one
day after injury, decompression of the injured area by surgery, and pain relief [1–4]. There
are no treatments for addressing the root causes or for restoring lost tissue, so gene and cell
therapies, in addition to drug treatments, are the subjects of intense neuronal-regeneration
research [5–7].
Stem cell therapy is a major field of research for SCI treatment. It has been reported
to inhibit secondary damage by reducing inflammation and fostering axon and myelin re-
generation. Preclinical and clinical studies have demonstrated effective stem cell therapies
using bone marrow-derived mesenchymal stem cells (B-MSCs), cord-blood-derived MSCs,
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adipose-derived MSCs, neural stem cells (NSCs), induced pluripotent stem cells (iPSCs),
embryonic-cell-derived oligodendrocyte progenitor cells (OPCs), and Schwann cells [2,8,9].
Among these, MSCs have been mostly used in SCI clinical trials. In these studies, the
effects of MSCs were reported to be anti-inflammatory, immunomodulatory, anti-apoptotic,
and paracrine, and included the release of neurotrophic factors. However, stem cells still
have the potential risk for providing pro-tumorigenic influences, immune rejection due to
pre-culture conditions, poor engraftment/differentiation/viability, and poor therapeutic
patient outcomes [8,10–13]. The origins of NSCs used for SCI research are from several
sources: fetal and embryonic stem cells, iPSCs, and via trans-differentiation [14]. NSCs
also have been shown to have neuroprotective and anti-inflammatory effects, the ability to
differentiate into neurons, and the ability to release neurotrophic factors. However, ethical
and safety concerns remain about potential tumorigenesis due to their sources [8]. Due to
these reasons, identification of other cell types for effective SCI therapies is needed, with
the possibility of pre-conditioning them or modifying their genes to enhance both their
survival and paracrine effect.
The neural crest stem cells (NCSCs) have been shown to migrate along nerve fibers for
wide distribution, where they give rise to a variety of neural crest (NC)-lineage cells ranging
from neurons and glia of the peripheral nervous system to non-neural cells, including
melanocytes, endocrine cells, endoneurial fibroblasts, pericytes, chondrocytes, osteoblasts,
and MSCs [15–20]. Even though these embryonic cells disappear quickly after birth,
studies have reported the existence of NCSC-like cells in a variety of postnatal NC-derived
tissues, including the dorsal root ganglion ganglion [21], gut [22], cornea [23], heart [24],
dental pulp [25], skin [26], hair follicle [27], carotid body [28,29], palatum [30], and bone
marrow [31]. These postnatal NSCS-like cells exhibit the ability to generate various types
of NC-lineage cells. Moreover, their niches are intimately associated with PN [18,32].
Adult PN studies have reported endoneurial cells with the NCSC-like phenotypes
expressing NC-related markers such as nestin, Pax3, and p75NTR [33,34], and a few studies
have successfully isolated PNSCs from adult sciatic nerves [35,36]. These cells had the
ability to differentiate into Schwann cells and into mesodermal-lineage cells and some were
also able to form spheroids. However, the reported methods were technically demanding,
time-consuming, and involved multiple steps, all of which resulted in low cell yields after
long isolation and culture times. Considering their neurogliogenic abilities, postnatal
PNSCs may represent a promising source for translational cell-based strategies applied to
neurological disorders.
Typically, most stem cells are cultured using two-dimensional (2D) monolayer culture
conditions and transplanted as single-cell suspensions. However, low biological efficacy
and a low engraftment rates in hostile transplant environments remain concerns, prevent-
ing their use clinically. To overcome some of these limitations, three-dimensional (3D)
culturing was developed. This approach was shown to be more effective as a therapeutic
strategy due to enhanced biological efficacy, cell survival, and engraftment compared to
conventional single-cell suspensions [37]. As an example of a typical 3D microstructure,
multicellular spheroids consist of both cell-to-cell and cell-to-extracellular matrix intercon-
nections, leading to enhanced structural stability and functional properties. Among many
varieties of culturing conditions, suspension-culture conditions have become widely used
to facilitate the formation of cell spheroids [38].
2. Results
2.1. 3D Organ Culture Supported Cell Renewal and Outgrowth of PNSCs
We adopted 3D hydrogel-supported organ culture to support in situ PNSC cell renewal
and migration from PN into the hydrogel. As shown in Figure 1A, the neutral collagen
hydrogel used here had a sol-to-gel transition property that allowed PN fragments to
be 3D encapsulated in the gel phase, and it enabled tissue fragments to provide a 3D
substratum for cell attachment, migration, and proliferation of PNSCs. During these
hydrogel-supported PN organ cultures, PNSC outgrowth into the hydrogel was initially
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observed within one day of culture, after which the outgrowth showed a time-dependent
increase. All hydrogel-supported PN cultures showed consistent cell outgrowth. After
14 days of culture, the migrated cells were isolated from the hydrogels by treatment with
0.01% collagenase type I, which led to the rapid degradation of collagen hydrogel but had
no lytic effect on tissue. The migrated PNSCs that were released from the hydrogels were
collected by centrifugation, suspended in cell-culture media, transferred to polystyrene
culture dishes, and then subcultured using monolayer culture conditions as described in
Methods and Materials.
Figure 1. Isolation and immunophenotypic characteristics of peripheral nerve-derived stem cells (PNSCs). (A) Hydrogel-
supported 3D organ culture of peripheral nerve (PN) supported cell migration/outgrowth. Cell migration/outgrowth
increased in a time-dependent manner. (B) Migrated PNSCs in the hydrogels were isolated and then cultured under
monolayer-culture conditions. PNSCs exhibited a bipolar spindle-shape appearance and expressed neural crest-specific
transcription factors. (C) Flow cytometry assessment demonstrated that isolated PNSCs expressed markers for neural
crest-lineage cells but did not express markers for myelin (P0), Schwann cells (S100β), or endothelial and hematopoietic
cells (CD31 and CD45, respectively).
We next assessed the immunophenotypic profiles of isolated and subcultured PNSCs.
PNSCs uniformly expressed Sox2, Sox9, and Sox10; these transcription factors specifically
identify NC-lineage cells (Figure 1B). We further investigated the immunophenotypic
profiles of isolated PNSCs using flow cytometry. As shown in Figure 1C, assessed PNSCs
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also expressed NC-specific markers (nestin, p75NTR, Sox10, and CD105), but not markers
for myelinating Schwann cells (P0 and S100b), endothelial cells (CD31), and hematopoietic
cells (CD45).
2.2. Isolated PNSCs Showed Multipotent Differentiation Potential for Ectomesoderm-Lineage Cells
In Vitro
To test whether PNSCs have the ability to differentiate into Schwann cells in vitro, cells
were seeded onto Ultra-Low attachment plates and cultured for seven days without any
differentiation-inducing factors. PNSCs assembled into spheroids and showed fascicular
arrangements of spindle-shaped cells, mimicking PN bundles (Figure 2A). These spheroid
PNSCs uniformly expressed Schwann cell-related markers (GFAP and S100β) as well as
myelin-specific markers (P0 and MBP), indicating that PNSCs have an ability to differentiate
into myelinating Schwann cells (Figure 2B). Next, we assessed whether isolated PNSCs
were to differentiate into neuroglia-lineage cells. After 14 days of differentiation-induction,
less than 10% of cells were neuron-like in appearance (extensive bipolar and branched
neurites that expressed NF200 and Tuj1; Figure 2C). Moreover, a majority of cells (>80%)
showed the typical bush-like morphology of protoplasmic astrocytes and expressed GFAP.
A minority of cells (<10%) demonstrated oligodendrocyte-like morphology and expressed
A2B5. A key feature of embryonic NC cells is the ability to differentiate into mesoderm-
lineage cells, such as adipocytes and osteocytes. To determine if PNSCs also had this
ability in vitro, PNSCs were induced to become adipocytes and osteocytes. These induced
PNSCs exhibited cytoplasmic accumulations of multivacuolated fat vacuoles and mineral
pigments, indicating that PNSCs have the ability in vitro to differentiate into adipocytes
and osteoblasts, respectively (Figure 2D).
Figure 2. Multipotent differentiation potential of isolated peripheral nerve-derived stem cells (PNSCs)
in vitro. (A) Isolated PNSCs were induced to become Schwann cell-like cells. Under suspension-
culture conditions for seven days, PNSCs formed multicellular spheroid structures with fascicular
arrangements. (B) Spheroid PNSCs expressed markers for committed Schwann cells (GFAP and
S100β) and for myelin (P0 and MBP). (C) PNSCs induced to become neuroglia-lineage cells ex-
pressed neuronal markers (NF200 and Tuj1), a glial marker (GFAP), and an oligodendrocyte marker
(A2B5). (D) PNSCs induced to become osteocytes and adipocytes exhibited depositions of mineral
crystals and cytoplasmic accumulation of fat vacuoles visualized by Alizarin Red and Oil Red O
staining, respectively.
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2.3. PNSC Spheroids Maintained the Immunophenotype of Schwann Cell-Lineage Cells and
Promoted Pro-Neurotrophic Activity
Under suspension-culture conditions, PNSCs self-assembled or aggregated to form
3D spheroids (Figure 3A). These spheroids exhibited tight adhesions between cells with
eukaryotic nuclei, and necrotic/apoptotic cells were not observed during three days of
culture. Immunofluorescent staining demonstrated cell-to-cell and cell-to-matrix adhesions
mediated by integrin-β1 (CD29) and β-catenin. Interestingly, the uniform deposition of
synthesized extra cellular matrix (ECM) in vitro (e.g., laminin and collagen type-IV) during
suspension culture was also detected in PNSC spheroids. These interactions between
cells and ECM may not only have led to increased structural integrity but may also have
activated cell-signaling pathways to regulate cell differentiation.
Figure 3. Structural, immunophenotypic, and biomolecular characteristics of peripheral nerve-derived stem cell spheroids
(PNSCs). (A) Under suspension-culture conditions for three days, PNSCs spontaneously assembled into spheroid structures.
(B) PNSC spheroids exhibited cell-to-cell and cell-to-matrix interconnections through integrin-β1 (CD29) and β-catenin,
respectively. Notably, the in vitro deposition of synthesized extracellular matrix in spheroids was observed. (C,D) PNSCs
and PNSC spheroids highly expressed and secreted neurotrophic factor mRNAs and proteins compared to mesenchymal
stem cells (MSCs) derived from bone marrow. *, p < 0.05 compared to MSCs, **, p < 0.01 compared to MSCs, †, p < 0.01
compared to PNSCs.
To determine the immunophenotypes of PNSC spheroids after three days of suspen-
sion culture, immunofluorescence staining was performed with antibodies to identify NC-
and Schwann cell-lineage cells. PNSC spheroids uniformly maintained their expressions
of NC-lineage markers, including nestin, p75NTR, and CD105 (Figure 2B). Moreover,
Int. J. Mol. Sci. 2021, 22, 4141 6 of 21
NC-specific transcription factors (e.g., Sox2, Sox9, and Sox10) were also maintained in
PNSC spheroids. Notably, markers representing further commitment to the Schwann-cell
lineage (e.g., GFAP, GAP43, and S100b) were also expressed in PNSC spheroids, whereas
these markers were not expressed in earlier PNSC experiments. However, markers for the
myelin sheath (MBP and P0) were not detected in PNSC spheroids. These immunopheno-
typic features suggest that PNSCs assembled in spheroids showed preferential differenti-
ation into the Schwann-cell lineage most similar to non-myelinating or dedifferentiated
Schwann cells.
Accumulating evidence suggests that 3D spheroids can significantly modulate a
variety of cell-signaling pathways to upregulate the expression of many functional genes
and enhance their therapeutic potential. To compare neurotrophic activities between
PNSCs and PNSC spheroids, we assessed the expression levels of neurotrophic factor
mRNAs and their secretion levels by qRT-PCR and ELISA, respectively. PNSCs expressed
high levels of neurotrophic factor mRNAs compared to their levels in MSCs. As expected,
3D spheroids significantly upregulated the expression levels of the neurotrophic factors
compared to PNSCs (p < 0.01) and MSCs (p < 0.01; Figure 3C). After collecting conditioned
media from PNSCs, PNSC spheroids, and MSCs, we determined the secretion levels
for the neurotrophic factors. Interestingly, PNSCs secreted high levels of glia-related
neurotrophic factors, including cell-line-derived neurotrophic factor (GDNF), insulin-like
growth factor (IGF), and interleukin (IL)-6, compared to levels in MSCs (p < 0.01; Figure 3D).
Both nerve growth factor (NGF) and neurotrophin-3 (NT-3) were detected in conditioned
media from PNSCs but not detected in MSCs. Moreover, the secretion levels of GDNF,
IGF, NGF, and NT-3 were significantly increased in PNSC spheroids compared to PNSCs
(p < 0.01). Collectively, PNSCs showed specific high expression and secretion of glia-
related neurotrophic mRNAs and factors, and the neurotrophic activity of PNSCs can be
potentiated through the formation of 3D spheroids.
2.4. PNSC Spheroids Improved Functional Recovery after SCI
To investigate the therapeutic effects of PNSCs, we used a compression-based SCI
model in rodents. PNSCs were directly injected either as single-cell suspensions or as
spheroids one week after injury. Open-field locomotor testing was performed weekly for
eight weeks and Basso, Beattie, and Bresnahan (BBB) scores were used to evaluate locomo-
tion [39]. After SCI, the SCI/phosphate-buffered saline (PBS) group showed significantly
decreased motor function. The SCI/PNSCs group (non-spheroid PNSCs) showed a slight
behavioral improvement, but it was not a significant change (Figure 4A). In contrast, BBB
scores gradually and significantly increased in the SCI/PNSC spheroids group (Figure 4A).
Eight weeks after injury, the mean SCI/PNSC spheroids BBB score was 10.175 ± 0.95,
indicating weighted walking using the hindlimbs. These results indicate that PNSCs have
therapeutic value, and that the spheroid form enhances it.
Int. J. Mol. Sci. 2021, 22, 4141 7 of 21
Figure 4. Peripheral nerve-derived stem cell (PNSC)-mediated functional recovery and neuronal regeneration. (A) BBB
scoring after SCI in all groups (Sham, SCI/PBS, SCI/PNSCs, and SCI/PNSC spheroids). A two-way ANOVA with Holm–
Šídák’s multiple comparisons was used for data analysis. (B) Hematoxylin and eosin staining of longitudinal spinal cord
sections in all groups for assessment of tissue regeneration. (C) Eriochrome cyanine (EC) staining of spinal cord cross sections
for myelin in all groups. (D) Total cord area remaining using EC imaging in Sham (n = 3), SCI/PBS (n = 4), SCI/PNSCs
(n = 6), and SCI/PNSC spheroids (n = 4) animals. Ordinary one-way ANOVA with Tukey’s multiple comparisons was used
for analysis. (E) Total cavity area from EC imaging. Ordinary one-way ANOVA with Tukey’s multiple comparisons was
used for analysis. All data are expressed as mean ± S.E.M.; * p < 0.05, ** p < 0.01, and *** p < 0.001.
To confirm correlations between functional recovery and tissue regeneration, the spinal
cords from each group were stained using hematoxylin/eosin and eriochrome cyanine (EC)
(Figure 4B,C). In the sham group, there was no evidence of spinal cord degeneration, but
large cavities and tissue shrinkage were observed in the SCI/PBS group. In the SCI/PNSCs
group spinal cords, there was also tissue shrinkage and the cavities were reduced, but still
severe. In contrast, spinal cord tissue was regenerated close to sham levels in the SCI/PNSC
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spheroids group (Figure 4B). In addition, the entire spinal cord area was restored, and the
cavity areas were significantly decreased in the SCI/PNSC spheroids group (Figure 4D,E).
As these results correlated well with the BBB scores it suggests that PNSCs induce spinal
cord regeneration, especially in the SCI/PNSC spheroids group, and are responsible for
the functional recovery.
2.5. PNSC Spheroids Reduced Mechanical Allodynia and Inflammation Following SCI
Previous reports have demonstrated that neuropathic pain can accompany SCI [40].
Here, we confirmed mechanical allodynia using a dynamic plantar test [41]. Mechanical
allodynia was measured beginning three weeks after the SCI when the animal hind paws
were facing down. The sham-operated group withdrew their hind paws using an average
force of 31 g. Three weeks after injury, animals in the SCI/PBS and SCI/PNSCs groups
were hypersensitive to mechanical stimulation. Eight weeks after injury, they were still
hypersensitive, removing their hind paws at 16.2 and 22.8 g, respectively. In contrast, the
SCI/PNSC spheroids group withdrew their paws at 15 g three weeks after injury, indicating
less sensitivity to stimulation compared to the SCI/PBS and SCI/PNSC groups. Overall,
the SCI/PNSC spheroids group showed mechanical allodynia improvement that was close
to sham eight weeks after SCI (Figure 5A).
Mechanical allodynia is only one form of neuropathic pain and the causes of neuro-
pathic pain after SCI are not known, but those suspected include immune responses, glial
cells, and myelin degeneration [40,42–44]. Here, we confirmed an inflammatory response
using the markers CD68 and IL-1β (Figure 5B). In all SCI animals, CD68 expression was
significantly increased, with no significant differences between the SCI/PBS, SCI/PNSCs,
and the SCI/PNSC spheroid groups (Figure 5B,C). However, IL-1β expression (a pro-
inflammatory cytokine implicated in neuropathic pain [45]) differed significantly between
groups. IL-1β expression was reduced to 33% in the SCI/PNSC spheroids group com-
pared to the SCI/PBS group (Figure 5B,D). This result also correlates with the mechanical
allodynia results and indicates that PNSC spheroids improve neuropathic pain.
2.6. PNSCs Survived Three Weeks after Transplantation and Affected Both Neurons and
Glial Cells
We assessed cell survival three days, three weeks, and seven weeks after cell trans-
plantation. Transplanted PNSCs were identified using HuN because they were originally
isolated from adult humans. Three days after transplantation, almost all cells survived,
but only 27% and 31% of cells survived three weeks after transplantation (compared to
the three-day numbers) in the SCI/PNSCs and SCI/PNSC spheroid groups, respectively
(Figure 6A,B). Seven weeks after transplantation, almost no HuN-positive cells were ob-
served in all groups (Figure 6A,B). These results indicate that single-cell suspensions
and PNSC spheroids do not survive long term, but they still affected the spinal cord
environment to improve functional behavior.
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Figure 5. Peripheral nerve-derived stem cell (PNSC)-mediated improvement in mechanical allodynia and inflammation.
(A) Mechanical allodynia assessment using a dynamic plantar test. Testing began three weeks after SCI and continued
until eight weeks after SCI. Data were analyzed by using a two-way ANOVA with Holm–Šídák’s multiple comparisons.
(B) Representative imaging showing DAPI (blue), anti-CD68 (green), and anti-IL-1β (red) staining eight weeks after SCI.
(C) Total CD68 staining intensity in all groups (Sham, n = 5; SCI/PBS, n = 13; SCI/PNSCs, n = 21; and SCI/PNSC spheroids,
n = 28). Ordinary one-way ANOVA with Tukey’s multiple comparisons was used for analysis. (D) Total IL-1β staining
intensity in all groups (Sham, n = 5; SCI/PBS, n = 13; SCI/PNSCs, n = 21; and SCI/PNSC spheroids, n = 28). Ordinary
one-way ANOVA with Tukey’s multiple comparisons was used for analysis. All data are expressed as mean ± S.E.M.;
* p < 0.05, ** p < 0.01, and *** p < 0.001.
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Figure 6. Viability and differentiation of transplanted peripheral nerve-derived stem cells (PNSCs). (A) Representative
confocal imaging showing DAPI (blue) and anti-HuN (green) staining three days, three weeks, and seven weeks after
transplantation. (B) Total number of HuN+ with DAPI+ cells per mm2. (C) Representative confocal imaging showing
anti-HuN (green), anti-Tuj1 (red), anti-MBP (blue), and anti-GFAP (white) eight weeks after injury. (D) Total Tuj1 staining
intensity in the Sham (n = 4), SCI/PBS (n = 5), SCI/PNSCs (n = 19), and SCI/PNSC spheroids (n = 19) groups. Ordinary
one-way ANOVA with Tukey’s multiple comparisons was used for analysis. (E) Total MBP staining intensity in all groups.
The n numbers and analysis was the same as for Tuj1. (F) Total GFAP staining intensity in all groups. The n sizes and
analysis were the same as for Tuj1. All data are expressed as mean ± S.E.M.; * p < 0.05, ** p < 0.01, and *** p < 0.001.
The PNSCs used in this study have the potential to differentiate into both neurons
and neuroglial cells. We therefore investigated the neurons, astrocytes, and oligodendro-
cytes with antibodies against Tuj1, GFAP, and MBP eight weeks after injury (Figure 6C).
Differentiated PNSCs were not observed because the cells did not survive seven weeks
after transplantation. Although differentiated cells were not observed, the expressions
of these neuronal and glial cell markers changed significantly. In the PNSC-transplanted
groups, the expressions of the neuronal marker Tuj1 and the oligodendrocyte marker MBP
increased, but expression of the astrocytic marker GFAP decreased (Figure 6C–F). This
was especially true for the SCI/PNSC spheroids group which showed the most marked
changes in all cell types; Tuj1 expression increased significantly to near-sham levels and the
expressions of the other markers was closer to sham levels compared to the other groups
(Figure 6C–F). These results indicate that PNSC viability is not sufficient; its paracrine
effects are required for the enhancement of recovery and is improved by the formation
of spheroids.
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2.7. Transplanted PNSCs Induced the Expression of Neurotrophic Factors
From the above results, the paracrine influence of transplanted PNSCs was expected to
be via neurotrophic factor expression (Figure 3C,D and Figure 6C). This was especially true
for the increases in GDNF and NT-3 expressions in PNSC spheroids (Figure 3C,D). Neu-
rotrophic factors play important roles in both neuroprotection and neuronal regeneration.
Three days after transplantation, NT-3 expression was significantly increased in both the
SCI/PNSC and the SCI/PNSC spheroid groups. Three weeks after transplantation, NT-3
expression was also increased in both of these PNSC groups. Even though increased NT-3
expression was not maintained in the SCI/PNSC group, it remained so in the SCI/PNSC
spheroids group (Figure 7A,C).
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Figure 7. The expressions of GDNF and NT-3 after SCI. (A) Representative confocal imaging, with blue indicating DAPI,
green indicating HuN, and red indicating either NT-3 or GDNF. (B) Total NT-3 staining intensity, with n = 5 for all groups.
Data were analyzed using a two-way ANOVA with Holm–Šídák’s multiple comparisons. (C) Total GDNF staining intensity,
with n = 5 for all groups. Data were analyzed using a two-way ANOVA with Holm–Šídák’s multiple comparisons. All data
are expressed as mean ± S.E.M.; * p < 0.05, ** p < 0.01.
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The other neurotrophic factor examined, GDNF, was also increased in the SCI/PNSC
and SCI/PNSC spheroid groups three days after transplantation similar to NT-3 (Figure 7B,D).
However, this increased GDNF expression was not maintained seven weeks after trans-
plantation, with levels close to those of the SCI/PBS group beginning three weeks after
transplantation in the SCI/PNSC and SCI/PNSC spheroid groups (Figure 7B,D).
2.8. PNSC Spheroids Enhanced Remyelination after SCI
Recovery after a SCI is related not only to neuronal regeneration but also to remyelina-
tion [46,47]. Here, we demonstrated PNSC spheroid myelination ability using EC staining
(Figure 4C) and using an antibody against MBP (Figure 6C). Seven weeks after transplanta-
tion, PNSC single-cell suspensions induced MBP expression (Figure 6C,E) and the entire
area was largely myelinated compared to the PBS transplanted group, but this change was
not statistically significant (Figure 4C). In contrast, PNSC spheroids significantly enhanced
MBP expression (Figure 6C,E) and myelination in the area was significantly increased so
that even gray and white matter could be distinguished from each other (Figure 4C). These
results indicate that PNSC spheroids can improve remyelination after SCI.
3. Discussion
Here, we report on the development of PNSC spheroids that: (1) can form as stable
spheres (100 ± 20 µm); (2) have immune expression characteristics similar to NC stem cells;
(3) have the ability to differentiate into neuronal and mesenchymal cells; (4) consistently
release several neurotrophic factors and anti-inflammatory factors; and (5) have improved
therapeutic ability in a SCI model.
Stem cell therapy represents one of the strategies for SCI treatment. Several stem cell
types have been used for SCI treatments, including B-MSCs, cord-blood-derived MSCs,
and NSCs. Because these stem cells have the potential for multilineage differentiation,
their transplantations were expected to engraft and replace damaged cells [2,8]. However,
the conditions within the injured environment make the survival of transplanted cells
difficult and lower the probability for both engraftment and differentiation [8,10–13]. For
these reasons, genetic modifications and preconditioning in vitro have been attempted to
increase any paracrine effects and to increase cell survival [48,49]. Stem cells have been
reported to inhibit secondary damage, have anti-inflammatory effects, protect host cells,
and produce neurotrophic factors [2,8,50]. The present report documents our development
of adult PNSCs and PNSC spheroids. Unlike the central nervous system, PNs have the
capacity for self-repair and regeneration. After a PN injury, the repair-type Schwann
cell is generated through the de-differentiation or reprogramming pathway. It plays
a central role in PN regeneration by releasing both neuroactive and anti-inflammatory
factors [51]. These repair-type Schwann cells also share similar features with NCSCs and
Schwann-cell precursors [51–53]. The adult PNSCs have similar immunophenotypes to
undifferentiated NCSCs. These PNSCs express neurotrophic factor mRNAs and proteins
for BDNF, GDNF, IGF-1, IL-6, NGF and NT-3. As mentioned above, stem cells have been
modified genetically and via preconditioning to improve therapy effectiveness. Here, we
developed PNSC spheroids with increased viability, which released several-fold increases
in neurotrophic factors and anti-inflammatory factors compared to non-spheroid PNSCs,
and which generated extracellular matrix components including fibronectin, laminin, and
collagen type-IV.
Because of these features, the long-term survival of these PNSC spheroids was three
weeks after transplantation. Although PNSCs did not survive seven weeks after transplan-
tation, regeneration was enhanced after spinal cord injury and they induced functional
recovery. In the SCI/PNSC spheroids group, the neuronal marker Tuj1 was significantly
increased, the astrocytic marker GFAP was significantly decreased and the final expression
levels for both markers approached those of the sham group. Although these PNSCs
demonstrated substantial differentiation potential and the possibility for engraftment via
ECM expression, the survival of transplanted PNSCs was not enough for engraftment
Int. J. Mol. Sci. 2021, 22, 4141 13 of 21
and differentiation. The effects of these PNSCs were based on paracrine influences of
neurotrophic factor expression. From the SCI/PNSC spheroids group, both GDNF and
NT-3 were highly and continuously expressed. These two factors are known to have both
neuroprotective effects and to induce neuronal regeneration [54–56]. Other changes, such
as the significant PNSC-mediated decrease in astrocytes, may have mixed outcomes after
SCI because reactive astrocytes have been shown to protect host cells from secondary
damage in acute-phase SCI, but can interrupt neuronal regeneration in chronic-phase SCI.
One of the increased neurotrophic factors, GDNF, is also known as a powerful protector
of neuronal cells, and is mostly expressed in glial cells [54–57]. GDNF has also been re-
ported to reduce GFAP expression and hypertrophy of reactive astrocytes [58]. It is likely
that GDNF reduced reactive astrocytes especially in the SCI/PNSC spheroids group and
that GDNF expression was relatively lower in the SCI/PNSC spheroids group. These
differences are also likely to account for the SCI/PNSC spheroids group showing the most
impressive functional recovery and regeneration. The other neurotrophic factor, NT-3, has
also been shown to prevent cell death, reduce atrophy, and to induce neuronal regenera-
tion [59]. In the SCI/PNSC spheroids group, NT-3 was significantly increased compared
to the other SCI groups, and its increased expression was maintained until seven weeks
after transplantation even though PNSCs no longer survived. All of these results can be
explained by PNSC paracrine effects; transplanted PNSCs and PNSC spheroids influenced
host cells and maintained that influence until seven weeks after transplantation. This can
also explain the increased GDNF expressed in astrocytes, and its rare expression in the
SCI/PBS group. In addition, most NT-3 and GDNF expression was seen in host cells seven
weeks after transplantations.
We have demonstrated not only PNSC-mediated functional recovery but also mitiga-
tion of neuropathic pain. Neuropathic pain is a commonly reported medical complication
in SCI patients [60–62]. Approximately 80% of patients suffer with pain during the acute
phase of SCI, and 30–50% of patients suffer from it chronically, so the use of pain-relief
medication is common in SCI patients [61]. Neuropathic pain due to SCI has several
causes: inflammation, changes in intracellular signaling, reactive oxygen species, and
demyelination [63,64]. Among these causes, SCI-induced demyelination can sometimes
lead to secondary damage and neuropathic pain due to hyperexcitability [64,65]. Such
demyelination can affect C-fibers by inducing the spontaneous stimulations that result in
both hyperalgesia and allodynia [66,67]. Due to this, remyelination in the injured spinal
cord is an important factor mediating functional recovery. Transplanted PNSC spheroids
had a strong remyelination effect in the present SCI model, likely mediated by their high
NT-3 expression. Previous reports have demonstrated that NT-3 increased mature oligoden-
drocytes and induced remyelination [68,69]. As an additional cause of neuropathic pain,
inflammation was also significantly reduced in the SCI/PNSC spheroids group. Overall,
the complex actions of PNSC spheroids improved both motor function and neuropathic
pain after SCI.
The MSCs derived from bone marrow (B-MSCs) have been widely used as a cell
therapeutic for the repair of SCI. Transplanted MSCs mediate their beneficial effect by
secreting anti-inflammatory and anti-apoptotic factors that mitigate a secondary inflamma-
tory response and cell death, respectively. However, the low secretion level of neurotrophic
factors was one of limitations for their therapeutic potential in functional and structural re-
covery of injured spinal cord. To overcome these limitations, fetal neural stem cells (NSCs)
have been tried based on their ability to secrete neurotrophic factors, which mediate their
neuroprotective effects. However, clinical translation of these cells was hindered by the
feasibility of obtaining sufficient quantities of tissue for isolating NSCs. In this manuscript,
we first demonstrate that PNSCs express and secrete high levels of glia cell-derived neu-
rotrophic mRNAs and factors that mediate their indirect neuroprotective effects. Moreover,
in practical situations, obtaining adult peripheral nerves for isolating stem cells is easier
than fetal tissue. Overall, the neurotrophic ability of PNSC might be used as a promising
cell source for the treatment of SCI.
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In conclusion, we have isolated adult stem cells from PNs with similar characteristics
to undifferentiated NCSCs. For a more effective therapeutic approach to SCI, we developed
PNSC spheroids using 3D culture. These PNSC spheroids showed a powerful therapeutic
effect in a SCI model compared to single-cell PNSC suspensions. However, both cell
differentiation and engraftment were not observed. Despite these limitations, these novel
spheroids may represent a new clinical treatment for managing SCI.
4. Materials and Methods
4.1. Reagents
The PNs used for cell isolation were obtained from common iliac nerve segments
harvested after brain death from human organ donors. This study was reviewed and
approved by the Institutional Review Board of Inje University Busan Paik Hospital. Porcine
skin-derived collagen (Matrixen®-PSC) and collagenase type I were obtained from SK
Bioland (Chunan, Korea) and Worthington Biochemical (Lakewood, NJ, USA), respectively.
Growth factors, including recombinant epidermal growth factor (EGF), basic fibroblast
growth factor (bFGF), β-nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), and transforming growth factor-β1 (TGF-β1), were purchased from Peprotech
(Seoul, Korea). Culture media, animal sera, and culture reagents were obtained from
Invitrogen (Seoul, Korea), unless otherwise specified.
4.2. 3D Organ Culture and Cell Isolation
After removing the epineurium and surrounding connective tissue using a stereomi-
croscope, PN segments were minced using a razor blade into 2- to 3-mm-long pieces,
washed with phosphate-buffered saline (PBS), and then suspended in a pre-chilled 0.25%
neutral collagen solution. A mixture of 100 mg nerve pieces suspended in 10 mL of neutral
collagen solution was transferred into a 100 mm tissue culture dish and then incubated in a
humidified chamber for 2 hr at 37 ◦C to establish a neutral collagen hydrogel that would
enable 3D encapsulation of the PN pieces. Fifteen milliliters of organ culture medium
(100 ng/mL EGF, 20 ng/mL bFGF, and 10 µg/mL gentamicin in Dulbecco’s Modified
Eagle Medium/Nutrient Mixture F-12 (DMEM/F12)) was added. Organ cultures were
performed under dynamic conditions in an orbital shaker at 25 rpm for two weeks. The
organ culture medium was replenished three times per week.
After 14 days of organ culture, collagen hydrogels containing PN fragments and
outgrown PNSCs were incubated with 0.01% collagenase type I at 37 ◦C under dynamic
conditions in an orbital shaker at 25 rpm for 30 min. When the hydrogels had degraded,
the migrated/outgrown PNSCs released from the hydrogels were collected, centrifuged
at 150× g for 10 min, and then suspended in cell culture medium (DMEM/F12 supple-
mented with 10 ng/mL EGF, 2 ng/mL bFGF, and 10% fetal bovine serum). These isolated
PNSCs were seeded in polystyrene (PS) culture dishes and expanded using conventional
monolayer-culture conditions. When the cells reached 80% confluence, PNSCs were de-
tached using trypsin-EDTA treatment, seeded at a density of 5000 cells per cm2, and then
subcultured at a 1:6 split ratio. This initial subculture under monolayer-culture conditions
was considered passage 1 (P1). Subcultured PNSCs were used at passage 6 (P6) to de-
termine transcriptional, immunophenotypic, and biologic properties, and at P5 for cell
transplantation experiments, unless otherwise specified. All assays were carried out using
three different batches of PNSCs and were performed at least twice for validation, unless
otherwise specified. MSCs were derived from bone marrow using a conventional method,
as described elsewhere [70], and used as negative controls. SH-SY5Y cells were obtained
from ATCC (Manassas, VA, USA) and used as positive controls.
4.3. 3D Spheroid Cultures
PNSCs expanded in vitro were collected after trypsin-EDTA treatment and resus-
pended in suspension-culture medium composed of DMEM/F12 supplemented with 0.1%
calf serum. PNSCs (7.5 × 106) were seeded in T75 Ultra-Low attachment cell culture flasks
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(Corning Inc., Corning, NY, USA). After 72 h of culture, established PNSC spheroids were
collected from plates, washed three times with PBS, and then suspended in 1 mL of PBS
(7.5 × 106 PNSCs) for transplantation.
4.4. Immunophenotype Analysis
The immunophenotypes of isolated and subcultured PNSCs were assessed by im-
munostaining using a set of antibodies against markers related to NC-lineage cells, Schwann
cells, neuroglia, endothelial cells, and hematopoietic cells (for supporting information,
see Table S1). The expression of a given marker was measured either by flow cytometry
(FACS CantoTM, BD Bioscience, San Jose, CA, USA) or using confocal microscopy (Zeiss
LSM 510 Meta, Gottingen, Germany). For immunofluorescence assessment, 3 × 104 cells
were seeded in 8-well chamber slides (Lab-Teck™ Chamber Slide System, Thermo Fisher
Scientific, Wilmington, DE, USA), cultured for one day, and then fixed using a 1:1 mixture
of acetone and methanol. After incubation with 5% bovine serum albumin (Fraction V,
IgG-free; Sigma Aldrich, Saint Louis, MO, USA) for 30 min, the cells were incubated with
primary antibodies at 37 ◦C for 2 h. Isotype-matched secondary antibodies conjugated
with Alexa Fluors (Invitrogen) were applied, and the cells were incubated at 37 ◦C for
30 min. Cell nuclei were counterstained with 2 µg/mL diamidino phenylindole (DAPI;
Invitrogen) and coverslips were applied using ProLong® Gold antifade reagent (Invit-
rogen). Immunophenotyping of PNSCs was further validated using flow cytometry by
incubating 2 × 105 PNSCs with primary antibodies, and then labeling them with Alexa
Fluor-conjugated anti-mouse, anti-rabbit, or anti-goat IgGs. A minimum of 10,000 events
and 3000 cells were assessed to determine expression by flow cytometry or confocal mi-
croscopy, respectively. To assess the immunophenotypic characteristics of PNSC spheroids,
they were washed with PBS, fixed with 3% paraformaldehyde for 10 min, rinsed with PBS,
and then permeabilized with 0.2% Triton X-100 PBS for 2 h. Spheroids were incubated for
1 h with primary antibodies, washed three times with PBS, and then incubated with the
appropriate Alexa Fluor-conjugated secondary antibodies. Nuclei were stained with DAPI
and images were obtained using a scanning confocal microscope.
4.5. In Vitro Differentiation Potential
To test the differentiation potential of PNSCs to become Schwann cells in vitro, we
used suspension-culture conditions. Briefly, 5 × 104 PNSCs were seeded in 12-multiwell
Ultra-Low attachment plates (Costar®, Sigma Aldrich) and the medium to induce Schwann
cell differentiation was added. After seven days using suspension-culture conditions, the
degree of Schwann cell differentiation was assessed by immunofluorescence staining, as
described above, using Schwann cell-related markers including GFAP, S100β, P0, and MBP.
The differentiation ability of PNSCs to become neuroglia-lineage cells was tested by
seeding 5 × 104 PNSCs onto fibronectin-coated coverslips in 24-well plates and adding
500 µL of neuroglia differentiation medium (DMEM/F12 supplemented with 50 ng/mL
NGF, 50 ng/mL BDNF, and 1 mM cyclic adenosine monophosphate (cAMP, Sigma Aldrich)).
After 14 days of culture, neuroglial differentiation was estimated by immunofluorescence
staining using antibodies against neuronal markers (NF200 and Tuj1) and those for glia
(GFAP and A2B5).
The adipogenic differentiation medium for PNSCs was composed of 90% DMEM,
10% CS, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma Aldrich), 1 µM dexamethasone,
0.2 unit/mL insulin (Sigma Aldrich), and 200 µM indomethacin (Sigma Aldrich). The
osteogenic differentiation medium was composed of 90% Minimum Essential Medium-
α supplemented with 10% CS, 0.1 µM dexamethasone, 10 mM β-glycerol phosphate
(Sigma Aldrich), and 50 µM ascorbic acid. These differentiation media were changed
twice per week. Adipogenic or osteogenic lineage differentiation was assessed either
by Oil Red O (Sigma Aldrich) or Alizarin Red S (Sigma Aldrich) staining for detecting
cytoplasmic accumulations of lipid droplets or the extracellular deposition of calcium
phosphate, respectively.
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4.6. mRNA Expression
Transcriptional phenotyping of isolated PNSCs was determined using quantitative
reverse transcription (RT)-polymerase chain reaction (PCR). Total RNA was obtained from
PNSCs, MSCs, and SH-SY5Y cells using TRI-reagent® (Molecular Research Center Inc.,
Cincinnati, OH, USA), according to the manufacturer’s instructions. The quantity of
RNA was determined using a spectrophotometer (NanoDrop® ND-1000, Thermo Fisher
Scientific, Wilmington, DE, USA). One microgram of RNA was reverse-transcribed using
random primers and SuperScript® VILOTM (Invitrogen) to generate first-strand cDNA.
This reaction was carried out in a GeneAmp 2400 PCR thermocycler (Applied Biosystems,
Carlsbad, CA, USA) for 10 min at 25 ◦C, 50 min at 42 ◦C, and 15 min at 70 ◦C, followed
by cooling to 4 ◦C. All PCR experiments were performed using an ABI Prism 7700 system
(Applied Biosystems, Carlsbad, CA, USA). All the amplifications were done using a SYBR
Green PCR Master Mix (Applied Biosystems). The thermal cycling conditions included
an initial denaturation step at 95 ◦C for 10 min, followed by 40 cycles at 95 ◦C for 30 s,
60 ◦C for 30 s, and 72 ◦C for 30 s. PCR melting-curve analyses were conducted after each
cycle. All samples were assayed in triplicate. For each sample, the expression of each
gene was normalized to the expression of a housekeeping gene (GAPDH mRNA) using
the 2-∆∆Ct method, where ∆Ct = Ct, reference gene—Ct, target gene. Dissociation curves
indicated that single products were obtained for each transcript. Information about the
specific primers used for the neurotrophic factor mRNA sequences is listed in Table S2.
4.7. Cytokine Assay
Conditioned media samples (CM) from monolayer and 3D spheroid cultures (DMEM/F12
supplemented with 0.1% calf serum) were collected after 72 h and concentrated using
Amicon® Ultra-15 centrifugal filter units (Millipore, Billerica, MA, USA). Neurotrophic fac-
tor concentrations were measured using commercially available ELISA kits (R&D Systems,
Minneapolis, MN, USA), including BDNF (DY248), GDNF (DY212), IGF (DY291), IL-6
(DY206), NGF (DY-256), and NT-3 (DY-267), according to the manufacturer’s instructions.
4.8. Spinal Cord Injury and Transplantation
In this study, SD rats (200 ± 20 g; OrientBio, Kyungki-do, Korea) were used and
kept in an animal facility permitted by the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC). All animals were anesthetized with ketamine
(100 mg/kg; Yuhan, Seoul, Korea), rompun (10 mg/kg; Bayer Korea, Seoul, Korea), and
isotropy 100 (Troikaa Pharmaceuticals Ltd., Gujarat, India). Spinal cords were exposed by
laminectomy in all animals. The exposed spinal cords of the SCI animals were compressed
at the T9 level for 10 s using self-closing forceps (Fine Science Tools, North Vancouver, BC,
Canada) [71]. Sham-group animals only had laminectomies without SCI. After surgery, the
SCI animals were randomly divided into three groups: SCI/PBS, SCI/PNSCs (transplanted
as single-cell suspensions), and SCI/PNSC spheroids (transplanted as spheroids). One
week after injury, transplants of either PBS, PNSCs, or PNSC spheroids (5 × 105 cells/5 µL
volume) were accomplished using a 27G Hamilton syringe. Injection rates were maintained
as 0.5 µL/min and the needle was kept in place for an additional 5 min after each injection.
After all surgical procedures, cefazolin (25 mg/kg; Chong Kun Dang, Seoul, Korea) was
administered for 5 days and cyclosporine (20 mg/kg; Chong Kun Dang) was administered
until the animals were sacrificed.
4.9. Open Field Testing
To assess functional recovery, open-field locomotor testing was performed weekly
for eight weeks after injury. BBB motor scores [39] were determined to quantify animal
movements. BBB scoring includes three-joint movement-angle ranges, weighted stepping,
gait coordination, and tail movement, and has a range of 0 to 21. A score of 0 indicates com-
plete paralysis and a score of 21 indicates normal movement. BBB scoring was performed
by two different investigators blinded to animal grouping.
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4.10. Mechanical Allodynia Measurement
Mechanical allodynia measurements were performed beginning three weeks after
injury when the animal hind paws were positioned facing down. For these measurements,
animals were placed in an acrylic enclosure on a wire-net platform for 10 min prior to
mechanical stimulation. Stimuli were applied to plantar hind paws using a Dynamic
Plantar Aesthesiometer (Ugo Basile, Comerio, Varese, Italy). A 0.5 mm diameter steel rod
was pushed into hind paws with gradually increasing force (0–50 g) over a 20 s period. If
the animal removes their hind paw from the rod, the stimulation stops automatically, and
the force and time are recorded.
4.11. Tissue Sample Preparation
Either three days or seven weeks after transplantation, animals were perfused with
saline and then fixed using 4% paraformaldehyde (PFA, Merck, Darmstadt, Germany).
Spinal cords were removed, immersion fixed in 4% PFA for 24 hr at 4 ◦C, and then
cryoprotected using 30% sucrose (Duchefa biochemie, Haarlem, The Netherlands) in
PBS for one week at 4 ◦C. The cryoprotected tissue was embedded in optimal cutting
temperature compound (Sakura Finetek, Torrance, CA, USA) and frozen at −80 ◦C. Tissue
sections (20 µm) were then cut using a cryostat.
4.12. Histology
4.12.1. Immunohistochemistry
Tissue sections were washed three times using ice-cold 0.3% Tween 20 (Sigma-Aldrich,
P1379) in PBS and blocked with 10% normal donkey serum (Jackson ImmunoResearch, West
grove, PA, USA) in PBS containing 0.3% Triton X-100 (Sigma-Aldrich, X100) for 1 hr at RT.
The blocked sections were incubated overnight with diluted primary antibodies including
mouse anti-HuN (1:300; Abcam, Cambridge, MA, USA), mouse anti-CD68 (1:300; Abcam),
goat anti-GFAP (1:500, Abcam), chicken anti-MBP (1:400, Abcam), rabbit anti-Tuj1 (1:2000,
Abcam), rabbit anti-IL-1β (1:500, Abcam), rabbit anti-NT-3 (1:200, Abcam), and rabbit anti-
GDNF (1:100, Abcam) in 10% NDS at 4 ◦C. After incubations, tissues were washed three
times with ice-cold 0.3% Tween 20 and treated with species-specific secondary antibodies,
including FITC-donkey anti-mouse IgG (H + L) (1:150, Jackson ImmunoResearch), CyTM3-
donkey anti-rabbit IgG (H + L) (1:600, Jackson ImmunoResearch), DyLightTM405-donkey
anti-chicken IgY++ (H + L) (1:600, Jackson ImmunoResearch), and CyTM5-donkey anti-
goat IgG (H + L) (1:200, Jackson ImmunoResearch) for 1 hr at RT. The slide-mounted tissue
was coverslipped using mounting solution with or without DAPI (Vector Laboratories,
Inc., Burlingame, CA, USA). Fluorescence imaging was observed and documented using a
scanning confocal laser microscope (LSM700, Carl Zeiss, Oberkochen, Germany).
4.12.2. Hematoxylin and Eosin Staining
Tissues were fixed with acetone and air-dried for 10 min. The dried tissue was then
rehydrated with PBS for 10 min and stained using hematoxylin (Sigma-Aldrich) for 50 s.
After this staining, the tissue was washed using distilled water for 5 min and then stained
with eosin (MERCK) for 40 s. The tissue was then dehydrated using graded ethanol
solutions (70%, 80%, 90%, and 100%). Permanent mounting medium (Fisher Scientific,
Hamptom, NH, USA) was used for tissue coverslipping, and a light microscope (IX71,
Olympus, Tokyo, Japan) was used to observe the staining.
4.12.3. Eriochrome Cyanine (EC) Staining
Tissue was fixed in acetone for 10 min and air-dried for 2 hr. The dried tissue was then
incubated in EC solution (MERCK, Kenilworth, NJ, USA) for 10 min at RT. After incubation,
the tissue was washed with running water and placed in 5% iron alum (MERCK) until the
gray matter was distinguishable. Tissues were differentiated using a borax-ferricyanide
solution (MERCK) and dehydrated through graded ethanol solutions (70%, 80%, 90%,
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and 100%). Permanent mounting medium was used for tissue coverslipping, and a light
microscope was used to observe the staining.
4.13. Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). The statistical
differences between groups were estimated by either a one-way or a two-way analysis
of variance (ANOVA) for multiple comparisons. The one-way ANOVA was performed
using Tukey’s post-hoc tests and the two-way ANOVA was performed using a mixed-
effects model. The p-values are indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001. All statistical analyses were performed using GraphPad PRISM 8.3
(GraphPad Software Inc, San Diego, CA, USA).
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22084141/s1, Table S1. The information of antibodies used in this study. Table S2. The
information of primers used in this study.
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